company background image
ALVM

Visiomed Group ENXTPA:ALVMG Stock Report

Last Price

€0.18

Market Cap

€42.7m

7D

-2.4%

1Y

-52.7%

Updated

25 May, 2022

Data

Company Financials
ALVMG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ALVMG Stock Overview

Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally.

Visiomed Group Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Visiomed Group
Historical stock prices
Current Share Price€0.18
52 Week High€0.46
52 Week Low€0.084
Beta-0.24
1 Month Change-4.60%
3 Month Change-3.84%
1 Year Change-52.69%
3 Year Change-87.92%
5 Year Change-99.74%
Change since IPO-99.94%

Recent News & Updates

Shareholder Returns

ALVMGFR Medical EquipmentFR Market
7D-2.4%4.4%-1.1%
1Y-52.7%-5.8%-5.9%

Return vs Industry: ALVMG underperformed the French Medical Equipment industry which returned -5.6% over the past year.

Return vs Market: ALVMG underperformed the French Market which returned -6.3% over the past year.

Price Volatility

Is ALVMG's price volatile compared to industry and market?
ALVMG volatility
ALVMG Average Weekly Movement20.2%
Medical Equipment Industry Average Movement7.0%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: ALVMG is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: ALVMG's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200767Thomas Picquettehttps://www.visiomed.fr

Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally. It provides thermometers, blood pressure monitors, pulse oximeters, connected blood glucometers, and connected electrocardiograms; and pain relief products, such as electrotherapy. The company also offers connected scales and scalable baby scales, as well as prevention and treatment products, such as humidifiers and phototherapies.

Visiomed Group Fundamentals Summary

How do Visiomed Group's earnings and revenue compare to its market cap?
ALVMG fundamental statistics
Market Cap€42.66m
Earnings (TTM)-€4.46m
Revenue (TTM)€7.18m

5.9x

P/S Ratio

-9.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALVMG income statement (TTM)
Revenue€7.18m
Cost of Revenue€7.79m
Gross Profit-€609.00k
Other Expenses€3.85m
Earnings-€4.46m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.019
Gross Margin-8.48%
Net Profit Margin-62.08%
Debt/Equity Ratio35.2%

How did ALVMG perform over the long term?

See historical performance and comparison

Valuation

Is Visiomed Group undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


3.03x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALVMG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALVMG's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALVMG is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Medical Equipment industry average.

PE vs Market: ALVMG is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALVMG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALVMG is overvalued based on its Price-To-Book Ratio (3x) compared to the FR Medical Equipment industry average (2.2x).


Future Growth

How is Visiomed Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-5.2%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Visiomed Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Visiomed Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALVMG is currently unprofitable.

Growing Profit Margin: ALVMG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALVMG is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare ALVMG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALVMG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).


Return on Equity

High ROE: ALVMG has a negative Return on Equity (-31.67%), as it is currently unprofitable.


Financial Health

How is Visiomed Group's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALVMG's short term assets (€16.0M) do not cover its short term liabilities (€23.5M).

Long Term Liabilities: ALVMG's short term assets (€16.0M) exceed its long term liabilities (€6.5M).


Debt to Equity History and Analysis

Debt Level: ALVMG has more cash than its total debt.

Reducing Debt: ALVMG's debt to equity ratio has reduced from 42.6% to 35.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALVMG has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALVMG has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.9% each year.


Dividend

What is Visiomed Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALVMG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALVMG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALVMG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALVMG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALVMG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.08yrs

Average board tenure


CEO

Thomas Picquette

0.083

Tenure

Mr. Thomas Picquette is Managing Director & Director of Visiomed Group SA from April 2022. He was a Senior Associate at Naxicap Partners. He joined the firm in January 2019 as a Senior Associate.He worked...


Board Members

Experienced Board: ALVMG's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 515.3%.


Top Shareholders

Company Information

Visiomed Group SA's employee growth, exchange listings and data sources


Key Information

  • Name: Visiomed Group SA
  • Ticker: ALVMG
  • Exchange: ENXTPA
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €42.655m
  • Shares outstanding: 233.60m
  • Website: https://www.visiomed.fr

Number of Employees


Location

  • Visiomed Group SA
  • 112, Avenue Kléber
  • Paris
  • Ile-de-France
  • 75116
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.